# Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

> **NCT01421017** · PHASE1,PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 31 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer
- Recurrent Breast Cancer

## Interventions

- **RADIATION:** Radiation
- **DRUG:** Imiquimod
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01421017
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-19
- **Primary completion:** 2016-07-01
- **Final completion:** 2016-08-06
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01421017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01421017, "Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01421017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*